Overview
Circio develops the circVec platform, a proprietary circular RNA expression system that enables higher and more durable protein production compared to linear RNA for gene and cell therapies. It supports AAV-delivered gene therapies in tissues like heart, eye, and CNS, and in vivo CAR-T cell therapy via partnerships such as with Acuitas Therapeutics. The company partners with pharmaceutical firms for preclinical validation and non-dilutive funding to advance applications in oncology, genetic diseases, and auto-immune conditions.
Frequently asked questions
- What is Circio's main technology platform?
- Circio's circVec platform uses circular RNA for enhanced gene expression in therapies, offering longer half-life, higher protein output, and potential for lower vector doses in AAV and cell therapies.
- What are Circio's key therapeutic applications?
- Applications include AAV gene therapy for heart, eye, CNS tissues; in vivo CAR-T for oncology and auto-immune diseases; and immunotherapy for cancers like melanoma and mesothelioma.
- Where are Circio's operations and partnerships located?
- R&D via Circio AB in Stockholm, Sweden; headquartered in Oslo, Norway; partnerships include a major pharma for preclinical validation and Acuitas Therapeutics in Vancouver, Canada.